Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2801-2820 of 3,900 trials

Gestational Trophoblastic Neoplasias: Avelumab and Methotrexate Study

We are investigating a new treatment combining Avelumab and Methotrexate for individuals with low-risk gestational trophoblastic neoplasias. This study aims to see if this combination is a safe and effective first-line option.

Gestational Trophoblastic Tumor>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and Obstetrics

CHF10073 Inhaled Drug Study

We are evaluating the safety and absorption of the inhaled drug CHF10073 in healthy adults, both alone and with itraconazole. This study aims to understand how the drug behaves in the body.

Idiopathic Pulmonary Fibrosis1-2 yearsSafety phase (I)Internal MedicinePulmonology

Ovarian Cancer: Tinzaparin and Biomarkers

We are studying how tinzaparin affects cancer marker levels in patients with advanced ovarian cancer receiving chemotherapy. This trial also looks at the drug's safety and its impact on immune and blood factors.

Epithelial Ovarian Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Primary Immune Thrombocytopenia: Efgartigimod IV Study

We are testing the safety and effectiveness of efgartigimod IV in adults with primary immune thrombocytopenia. This study will help us understand if it can improve platelet counts and reduce bleeding risks.

Idiopathic Thrombocytopenic Purpura (ITP)>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Ongoing Safety Study for Patients in Previous Trials

We are monitoring the safety of a treatment for patients who have participated in earlier studies. This study aims to ensure continued support and care for their health.

Chronic Lymphocytic Leukemia (CLL)B-cell Non-Hodgkin's Lymphoma (NHL)>2 yearsSafety phase (I)Post-Trial Drug AccessHematologyOncology

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Glioblastoma: 131I-TLX101 Treatment Study

We are testing a new treatment combined with standard care for patients newly diagnosed with glioblastoma. The goal is to find a safe dose and understand how well it works.

Glioblastoma Multiforme>2 yearsSafety phase (I)Oncology

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Myocarditis: Anakinra Treatment Study

We are investigating whether adding Anakinra to standard treatments helps patients with virus-negative myocarditis. This study aims to evaluate its safety and effectiveness compared to usual care.

Virus-Negative Myocarditis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Kidney Transplant: Alkaline Phosphatase Treatment

We are studying whether alkaline phosphatase can help prevent kidney injury after transplantation in deceased donor recipients. This may reduce the need for dialysis and improve kidney function recovery.

End-Stage Kidney DiseaseEfficacy phase (II)Investigational MedicinesInternal MedicineNephrology

Artificial Cornea for Severe Corneal Ulcers

We are studying a new human-made cornea for patients with advanced corneal ulcers that don't improve with standard treatments. The trial aims to assess its safety and effectiveness in these challenging cases.

Corneal Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Decompensated Cirrhosis: New Human Albumin Solution

We are studying a new human albumin solution to see if it is safer and more effective than the standard treatment for patients with decompensated cirrhosis. This research aims to improve clinical outcomes for those needing long-term albumin therapy.

Decompensated Cirrhosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyInternal Medicine

OCTAPLEX for Major Bleeding in Patients on Blood Thinners

We are studying whether a higher dose of OCTAPLEX can effectively stop major bleeding in patients taking direct oral anticoagulants. The trial also looks at the safety of this treatment during emergencies.

Coagulation DisorderAcute Major Bleeding with DOAC Therapy≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHematology

Atopic Dermatitis: RO7790121 Treatment Study

We are testing a new medication, RO7790121, for people with moderate to severe atopic dermatitis. The study aims to see if it can significantly improve skin symptoms compared to a placebo.

Atopic DermatitisEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Preventing Heart Issues in Cancer Patients: Empagliflozin Study

We are studying whether empagliflozin can help prevent heart problems in cancer patients undergoing chemotherapy with anthracyclines. We will compare its effects to a placebo to assess safety and effectiveness.

Cardiotoxicity1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyOncology

Hematologic Malignancies: Gene-Modified T Cell Therapy

We are exploring a new treatment using modified T cells for patients with certain blood cancers who have received a transplant from specific donors. The study aims to see if this approach is safe and effective.

Hematological Malignancies with Specific HLA-DPB1 MarkersSafety phase (I)Efficacy phase (II)HematologyInfectious Diseases

Metastatic Urothelial Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a new combination of livmoniplimab and budigalimab for adults with metastatic urothelial carcinoma who have not responded to prior treatments. The goal is to see if this combination improves survival compared to standard chemotherapy.

Urothelial CarcinomaMetastatic Urothelial CarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOncology

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Advanced Solid Tumors: BMS986504 Study

We are investigating how the drug BMS986504 is processed in patients with advanced solid tumors that have a specific genetic deletion. This study may provide insights for future cancer treatments.

Malignant Solid Tumor1-2 yearsSafety phase (I)Oncology